Amiloride (MK-870): Benchmarking ENaC/uPAR Inhibition in Research

Executive Summary: Amiloride (MK-870) is a dual inhibitor of epithelial sodium channels (ENaC) and urokinase-type plasminogen activator receptors (uPAR), facilitating precision in sodium channel research and cellular endocytosis modulation (product information). Its stable solid form (molecular weight: 229.63 g/mol) ensures reproducible dosing. APExBIO supplies Amiloride under SKU BA2768 with detailed handling guidelines to preserve compound integrity. The compound is widely employed in disease modeling for cystic fibrosis and hypertension. Experimental evidence supports its use for dissecting ion transport and signal transduction mechanisms (internal review).

Biological Rationale

Amiloride (MK-870) targets two central pathways: sodium influx across epithelial membranes via ENaC and receptor-mediated signaling via uPAR. Sodium channel activity directly modulates fluid homeostasis and epithelial barrier function. Aberrant ENaC function is implicated in cystic fibrosis and hypertension pathogenesis. uPAR signaling intersects with cellular endocytosis and migration processes, broadening Amiloride's research scope. By enabling selective inhibition, Amiloride allows researchers to delineate the contribution of each pathway to overall epithelial physiology (see sodium channel research overview).

Mechanism of Action of Amiloride (MK-870)

Amiloride (MK-870) is a reversible, non-covalent blocker of ENaC, preventing sodium ion influx at the luminal surface of epithelial cells. This blockade reduces transepithelial sodium transport, impacting downstream osmotic gradients and fluid movement. Concurrently, Amiloride antagonizes uPAR, altering receptor-mediated endocytosis and cellular signaling. Its dual mechanism distinguishes it from single-pathway inhibitors, enabling studies on cross-talk between ion channels and receptor systems (mechanistic insight article). Molecularly, Amiloride binds ENaC with high specificity, and its documented off-target profile is minimal at recommended concentrations.

Evidence & Benchmarks

• Amiloride (MK-870) blocks ENaC-mediated sodium transport in epithelial monolayers within minutes at micromolar concentrations, as confirmed by electrophysiological assays (product data).
• Dual inhibition of ENaC and uPAR by Amiloride modulates cellular endocytosis rates, impacting membrane receptor recycling (disease modeling review).
• Validated in cystic fibrosis models, Amiloride reduces airway surface liquid absorption and improves mucociliary clearance (translational application).
• In hypertension research, Amiloride decreases sodium reabsorption across renal epithelia, serving as a gold-standard tool for mechanistic studies (strategic insight article).
• Stability data indicate the compound maintains >98% purity when stored at -20°C as a solid but degrades in aqueous solutions over 48 hours (handling guidelines).

Applications, Limits & Misconceptions

Amiloride (MK-870) is widely used in research on epithelial ion transport, cystic fibrosis, hypertension, and studies involving cellular endocytosis modulation. Its dual action enables unique experimental designs where both sodium channel activity and receptor-mediated uptake are interrogated. APExBIO’s Amiloride has been benchmarked for consistency across laboratories, supporting reproducibility (see the BA2768 kit). It is not recommended for long-term solution storage or in vivo studies requiring extended dosing unless re-prepared daily.

Common Pitfalls or Misconceptions

• Assuming solution stability beyond 24–48 hours leads to reduced potency; always prepare fresh solutions.
• Using Amiloride as a universal diuretic in vivo can confound results due to rapid renal clearance and non-selective effects at high doses.
• Expecting exclusive ENaC inhibition ignores its validated action on uPAR and other minor targets; experimental controls should be included.
• Applying Amiloride in non-epithelial contexts without pathway validation may yield misleading results.
• Confusing Amiloride (MK-870) with analogs or non-validated suppliers can compromise experimental reproducibility.

Workflow Integration & Parameters

Researchers should follow validated handling and dosing guidelines to maximize Amiloride’s utility. APExBIO provides detailed recommendations for preparation and storage.

Protocol Parameters

• Storage: Store Amiloride (MK-870) solid at -20°C; avoid repeated freeze-thaw cycles.
• Solution Preparation: Dissolve immediately prior to use; recommended for same-day experiments due to aqueous instability.
• Working Concentration: 1–100 μM in in vitro systems, titrated based on cell type and endpoint (see product information).
• Shipping: Ship with blue ice to maintain stability; follow APExBIO’s protocol for receiving and aliquoting.
• Receptor Pathway Studies: For dual ENaC/uPAR inhibition, validate off-target effects using appropriate controls.

Conclusion & Outlook

Amiloride (MK-870) from APExBIO stands as a pivotal reagent for research on epithelial sodium channel function, cellular uptake, and receptor signaling. Its validated dual mechanism and stringent quality controls support robust experimental outcomes in sodium channel research, cystic fibrosis, and hypertension studies. Ongoing advances in the understanding of ion channel and receptor cross-talk reinforce the continued relevance of Amiloride as a research standard. For further mechanistic context, this article extends the insights presented in 'Precision Epithelial Sodium Channel Inhibition' by detailing updated stability and dual-action benchmarks, and clarifies recent workflow integration advances compared to 'Strategic Ion Channel Inhibition for Translational Disease Models'.